The UK has made a significant advancement in obesity treatment by approving Wegovy, an oral version of the weight loss drug semaglutide. This marks the first time a GLP-1 receptor agonist pill has been authorised for weight management in the UK, providing a new option for patients who have struggled with injectable forms of the medication, which have faced supply issues.
However, the availability of Wegovy through the National Health Service (NHS) is still pending. The medication is prescription-only and is intended for adults with a Body Mass Index (BMI) of 30 or greater, or those with a BMI between 27 and 30 who also have weight-related health conditions. This means that access will be limited and dependent on specific eligibility criteria.
Patients must also commit to lifestyle changes, including a calorie-reduced diet and increased physical activity, to achieve the best results. This requirement underscores the importance of combining medication with healthy habits, as pharmaceutical treatments are most effective when paired with behavioural modifications.
While the approval is a positive step, potential users should be aware of common side effects such as gastrointestinal issues. The next step for NHS patients will be an assessment by the National Institute for Health and Care Excellence to determine broader access to this new treatment option.
Source: GB News
